3552 Advancing Glioblastoma (GBM) drug regimen development to support combination therapy through integrated PKPD modeling and simulation-based predictions

OBJECTIVES/SPECIFIC AIMS: Despite advancements in therapies, such as surgery, irradiation (IR) and chemotherapy, outcome for patients suffering from glioblastoma remains fatal; the median survival rate is only about 15 months. Even with novel therapeutic targets, networks and signaling pathways bein...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Saugat, Shannon, Harlan E., Pollok, Karen E., Stratford, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2019
Materias:
Basic/Translational Science/Team Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808208/
http://dx.doi.org/10.1017/cts.2019.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808208/
http://dx.doi.org/10.1017/cts.2019.7

Ejemplares similares